PH-804 ACT / Phio Pharma - LARVOL DELTA

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th (PRNewswire) - 'Phio Pharmaceuticals...announced the results of several studies of its INTASYL™ compounds....The posters will be presented on November 10th and 11th at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held in Boston, MA from November 8 – 12, 2022."

P1 data • Preclinical • Breast Cancer • Melanoma • Oncology • Solid Tumor

Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment (PRNewswire) - "Phio Pharmaceuticals...announced positive data from an in vivo study that shows the strong antitumoral efficacy of individual INTASYL pipeline products, including PH-762, PH-790 and PH-804, can be further improved by combining them in a single therapeutic....'Recent study results with systemic immune checkpoint blockade antibody therapies shows promise of combination therapy, but the serious immune-related adverse events seen with such antibody therapy results in significant hurdles for realizing their maximum clinical potential when these antibodies are used in combination."

Preclinical • Oncology

Phio presents additional data supporting potential of TIGIT targeting INTASYL compound in the tumor microenvironment at AACR 2020 (PRNewswire) - "In an in vivo study, tumor growth inhibition was determined for both PH-804 and an anti-TIGIT antibody in colorectal carcinoma tumor bearing mice. Results from the study demonstrated that our INTASYL compound was efficiently delivered intratumorally to immune cells, resulting in a dose dependent inhibition of tumor growth, reaching statistical significance levels for PH-804 and anti-TIGIT antibody treatment arms...In addition, analysis of the TME of the PH-804 treated mice showed a dose dependent increase in cytotoxic effector T cells, and a dose dependent activation of such T cells as shown by the expression of activation makers such as CD25 and CD69."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology

Phio Pharmaceuticals reports year end 2019 financial results and provides business update (PRNewswire) - "The Company expects that PH-762 can be ready to enter the clinic with a partner in ACT therapy in the second half of 2020, and for direct therapeutic use towards the TME through intra-tumoral injection in 2021...In addition, in recent in vivo studies by the Company it was shown that intra-tumoral injections of a mouse version of PH-804 reduced the tumor growth in colorectal carcinoma tumor bearing mice. The Company is developing PH-804 with the aim to enter the clinic with a partner in ACT therapy in 2021."

New trial • Preclinical